Oncolytics Biotech (NASDAQ:ONCY) Earns “Buy” Rating from HC Wainwright

Oncolytics Biotech (NASDAQ:ONCY)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2029 earnings at $1.10 EPS.

A number of other research analysts have also recently issued reports on the stock. Leede Financial cut shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday, November 13th. Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.

Oncolytics Biotech Price Performance

Shares of Oncolytics Biotech stock opened at $0.72 on Monday. The business has a 50-day simple moving average of $0.85 and a 200 day simple moving average of $0.97. The firm has a market capitalization of $57.37 million, a price-to-earnings ratio of -2.66 and a beta of 1.24. Oncolytics Biotech has a one year low of $0.67 and a one year high of $1.53.

Hedge Funds Weigh In On Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Vantage Point Financial LLC purchased a new position in Oncolytics Biotech Inc. (NASDAQ:ONCY) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 29,744 shares of the company’s stock, valued at approximately $27,000. Institutional investors and hedge funds own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.